1. Demonstration of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Antiplatelet Effect of PZ-128 in Subjects with Multiple Coronary Artery Disease Risk Factors
The primary purpose of this study is to determine the safety and potential side effects of the investigational antiplatelet agent, PZ-128. The trial also seeks to demonstrate platelet function inhibition with PZ-128 in subjects with multiple CAD risk factors.
2. Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)
The purpose of this study is to find a correlation between certain blood
markers and the growth of the plaques, regardless of the presence of
the classic risk factors for atherosclerosis. If we prove our
hypothesis, we will be one step closer to predicting the extent of
atherosclerosis by performing certain blood tests.
3. Overcoming High on-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy with Ticagrelor: The HEIGHTEN Study
The objective of this study is to determine if ticagrelor is a better option than prasugrel for overcoming HPR, a risk factor associated with recurrent ischemic events. The study also seeks to determine the safety and tolerability of switching from prasugrel to ticagrelor and vice versa.
4. Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Angina, NSTEMI and STEMI Undergoing PCI: The Sinai COPERNICUS Study
The purpose of this study is to determine if ticagrelor therapy is associated with equivalent platelet inhibition irrespective of disease status in patients undergoing PCI. The pharmacodynamic effect of ticagrelor in patients undergoing PCI has not been studied in detail at this time.
5. AXERA Access Safety and Efficacy Post Endovascular Intervention (ASPEN)
The purpose of this study is to assess the safety and effectiveness of the AxeraTM
Access System when it is used on patients undergoing an interventional procedure.
6. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the
Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects
with a History of Chronic Angina Who Undergo Percutaneous Coronary
Intervention with Incomplete Revascularization
The objective of this study is to evaluate the efficacy of ranolazine, as compared with the placebo,
when used as part of standard medical therapy in chronic angina subjects
with incomplete revascularization post-percutaneous coronary
intervention (PCI) on the composite of ischemia riven revascularization
or ischemia-driven hospitalization without revascularization.
7. Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein
Inhibition with Evacetrapib in Patients at a High-Risk for Vascular
Outcomes – the ACCELERATE Study
The purpose of this study is to test if evacetrapib 130 mg daily, in
comparison to a placebo, reduces the incidence of cardiovascular death,
myocardial infarction, stroke, coronary revascularization or
hospitalization for unstable angina in high-risk vascular disease (HRVD)
patients. In addition, it’s designed to test if evacetrapib 130 mg
daily in HRVD patients, when compared to a placebo, increases
high-density lipoprotein-cholesterol (HDL-C) at 3 months after
randomization and decreases low-density lipoprotein-cholesterol (LDL-C)
at 3 months after randomization.
8. A prospective, Multi-center, Randomized, Double-blind Trial to Assess
the Effectiveness and Safety of 12 Versus 30 Months of Dual
Antiplatelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary
Intervention (PCI) with Either Drug-Eluting Stent (DES) or Bare Metal
Stent (BMS) Placement for the Treatment of Coronary Artery Lesions (DAPT
The aim of DAPT study is to identify the optimal duration of dual
antiplatelet therapy in subjects who undergo stenting procedures.